Tabituximab Biosimilar – Anti-FZD10 mAb – Research Grade

Description of Tabituximab Biosimilar - Anti-FZD10 mAb - Research Grade

Introduction

Tabituximab Biosimilar, also known as Anti-FZD10 mAb, is a research grade monoclonal antibody that has shown promising results in preclinical studies as a potential therapeutic agent. This antibody targets the Frizzled-10 (FZD10) protein, which is a key receptor involved in several signaling pathways implicated in cancer and other diseases. In this article, we will delve deeper into the structure, activity, and potential applications of Tabituximab Biosimilar.

Structure of Tabituximab Biosimilar

Tabituximab Biosimilar is a recombinant, humanized monoclonal antibody that is produced in a mammalian cell expression system. It belongs to the immunoglobulin G (IgG) class of antibodies and has a molecular weight of approximately 150 kDa. The antibody consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the target protein, FZD10, while the constant region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Tabituximab Biosimilar

Tabituximab Biosimilar specifically targets the FZD10 protein, which is a member of the Frizzled family of transmembrane receptors. FZD10 is overexpressed in a variety of cancers, including breast, lung, and pancreatic cancer, and has been implicated in tumor growth, invasion, and metastasis. By binding to FZD10, Tabituximab Biosimilar blocks the activation of downstream signaling pathways, including the Wnt/β-catenin pathway, which is known to promote tumor growth and progression. In addition, the binding of Tabituximab Biosimilar to FZD10 can also induce internalization and degradation of the receptor, further inhibiting its activity.

Furthermore, Tabituximab Biosimilar has been shown to have potent anti-angiogenic effects. FZD10 has been identified as a key regulator of angiogenesis, the formation of new blood vessels, which is essential for tumor growth and metastasis. By targeting FZD10, Tabituximab Biosimilar can inhibit the formation of new blood vessels, thereby limiting the blood supply to tumors and hindering their growth.

Applications of Tabituximab Biosimilar

The promising preclinical data on Tabituximab Biosimilar has led to its evaluation as a potential therapeutic agent in various cancer types. In a phase I clinical trial, Tabituximab Biosimilar showed promising results in patients with advanced solid tumors, with manageable side effects. Currently, there are ongoing clinical trials evaluating the efficacy and safety of Tabituximab Biosimilar as a monotherapy or in combination with other treatments, such as chemotherapy and immune checkpoint inhibitors, in different cancer types.

In addition to its potential as a cancer therapy, Tabituximab Biosimilar has also shown promise in other diseases where FZD10 is involved. For instance, FZD10 has been implicated in pulmonary fibrosis, a chronic lung disease characterized by scarring and impaired lung function. In preclinical studies, Tabituximab Biosimilar has been shown to reduce lung fibrosis and improve lung function, suggesting its potential as a treatment for this condition.

Conclusion

In summary, Tabituximab Biosimilar is a research grade monoclonal antibody that specifically targets the FZD10 protein. Its unique mechanism of action, which includes blocking signaling pathways and inhibiting angiogenesis, makes it a promising therapeutic agent for various cancers and other diseases. Ongoing clinical trials will provide further insights into the efficacy and safety of Tabituximab Biosimilar, and if successful, it could potentially become an important treatment option for patients in the future.